

# VACCINE DEVELOPMENT



**Discovery • Proof of Concept • Preclinical Toxicology • Clinical Support • Mfg Support**

Advancing vaccine candidates from research through IND submission requires careful confirmatory studies from *in vitro* screening and *in vivo* efficacy through GLP toxicology and safety studies.

IITRI offer a complete collection of preclinical services for vaccines against a wide range of bacterial and viral pathogens including select agents, influenza, Zika, and other emerging infectious diseases. IITRI provides IND-enabling vaccine programs, with over 30 years' experience conducting GLP-compliant toxicology studies. We support vaccine basic research through FDA approval programs for sponsors from government, biotech, academic, and pharma institutions.

## **IN VIVO ANIMAL CHALLENGE**

- Rodent, non-rodent, NHP
- Viral, bacterial, toxins
- Animal model development
- Biosafety Level (BSL)-2/3

## **GLP VACCINE TOXICOLOGY**


- Rodent, non-rodent, NHP
- All dosing routes including inhalation
- Immunogenicity analysis

## **SUPPORTING IN VITRO ASSAYS**

- ELISA
- PRNT
- Microneutralization
- HA (influenza)

## **IMMUNOPHENOTYPING**

- Cytokine analysis
- Flow cytometry
- ELISpot



## **THE IITRI ADVANTAGE**

- Highly experienced team of scientists provided for each study
- Specializing in both infectious disease and GLP toxicology
- Hands-on study directors are easily accessible, keeping you personally connected to your study
- BSL 2/3 facilities and vivarium

# CORE SERVICES

## IITRI (IIT Research Institute)


10 West 35th Street  
Chicago, IL 60616  
t: 312-567-4487

## CONTACT US

Todd Bucciarelli, MBA  
Director, Business Development  
t: 312-567-4924  
e: tbucciarelli@iitri.org



[www.iitri.org](http://www.iitri.org)



## DISCOVERY & DEVELOPMENT

### BSL-2/3+

#### Bacterial and viral strain library:


- Influenza, flavivirus (Zika, West Nile, dengue), VEE/ WEE/EEE, *B. anthracis* (anthrax), *Y. pestis* (plague) and Methicillin-resistant *Staphylococcus aureus* (MRSA)

#### In vitro efficacy studies

- Viral, bacterial

#### In vivo efficacy studies

- Rodent, cotton rat, rabbit, ferret, minipig



## GLP SAFETY & TOXICOLOGY

### Biodistribution (non-GLP)

- ELISA
- qPCR, RT-qPCR

### Repeat-dose GLP toxicology studies

- BSL-2
- All relevant routes of administration including inhalation
- Rodent, rabbit, minipig, canine, NHP
- Histopathology, clinical chemistry
- Immunogenicity, immunotoxicology

### Safety pharmacology



## SUPPORTING ASSAYS (GLP AVAILABLE)

### BSL 2/3+

#### Antibiotic potency

- MIC

#### Immunogenicity

- ELISA
- Plaque-reduction neutralization (PRN)
- Microneutralization (MN)
- Hemagglutination assay (HI)
- Yield-reduction assay

#### Modulation of cytokine expression

- Assessment of biomarkers
- Immunophenotyping (FACS)



## MANUFACTURING SUPPORT

### BSL 2/3+

#### Batch release testing (GMP)

#### Potency testing

- In vitro efficacy studies
- In vivo efficacy studies